There could be big returns waiting for investors in the healthcare sector according to analysts at Bell Potter.

In fact, the ASX healthcare share in this article is being tipped to almost double in value from current levels.

Which ASX healthcare share?

The share in question is Neuren Pharmaceuticals Ltd (ASX: NEU).

It is a biotechnology company with two novel drug assets. Bell Potter notes that the most advanced is Daybue (trofinetide), which was out-licensed to Acadia (NASDAQ: ACAD).

The ASX healthcare share’s second asset, NNZ-2591, is under development for multiple rare diseases. The most advanced is Phelan McDermid syndrome.

Neuren Pharmaceuticals is currently conducting a Phase three trial in Phelan McDermid syndrome and has conducted Phase 2 trials in three other rare neurological conditions.

Bell Potter believes the market is ascribing no value to NNZ-2591, which it feels has created a compelling buying opportunity for investors.

At the same time, it highlights that European regulators have reversed a negative recommendation on Daybue in the region, putting it on a likely path to approval.

Commenting on this, Bell Potter said:

The addition of Daybue European sales adds ~$2/share to our NPV valuation based on current forecasts. We estimate the future value of Daybue licensing income to be ~$9.50 (comprising ~$7.50 from the US and ~$2 from Europe). The existing ~A$300m cash balance equates to ~$2.50/share. Hence a total value of ~$12/share for cash + Daybue licensing income, excluding any contribution from NNZ-2591.

At the latest closing price, we therefore see effectively zero implied value for NEU’s second asset, which in itself would be a multi-billion-dollar value asset should it succeed in the Phase 3 trial. The Phase 3 remains in the early stages of recruitment, with results not expected until the end of CY27 at the very earliest (pending recruitment pace).

Big potential returns

According to the note, Bell Potter has retained its buy rating on the ASX healthcare share with an improved price target of $23.50 (from $22.00).

Based on its current share price of $12.20, this implies potential upside of approximately 93% for investors over the next 12 months. It said:

We maintain our BUY recommendation and increase PT to $23.50.

To put that into context, a $5,000 investment would turn into approximately $9,650 by this time next year if Bell Potter is on the money with its recommendation.

The post Bell Potter says this ASX healthcare share could rise 93% (It’s not CSL) appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX blue-chip shares can be among the best options for passive income because of both their dividend yields and the stability they provide.

Businesses that are market leaders in their sector can be a very effective choice because they are much stronger than competitors, with scale and margin advantages.

The two businesses below have a strong track record of paying dividends, and I expect compelling dividend payouts in the months and years ahead.

JB Hi-Fi Ltd (ASX: JBH)

JB Hi-Fi is one of the leading retailers in Australia and New Zealand, with its JB Hi-Fi Australia, JB Hi-Fi New Zealand, The Good Guys and E&S Trading businesses.

The ASX blue-chip share is arguably the market leader in electronics and appliances in Australia, and it continues to work on improving its position through new stores, increased scale, and a low-cost operating model.

JB Hi-Fi has grown its annual dividend in most years over the last 13 years, which is impressive to me for a retailer.

The business doesn’t typically trade on a high price/earnings (P/E) ratio, which means its dividend yield can be attractive.

According to Commsec’s projection, the business is forecast to pay an annual dividend per share of $3.38 in FY26. That translates into a possible grossed-up dividend yield of 5.9%, including franking credits.

Electronics and appliances remain an essential element for many households, so I expect the company can deliver fairly defensive earnings during this period of higher inflation and interest rates (again).

Telstra Group Ltd (ASX: TLS)

Telstra is Australia’s leading telecommunications business with the most subscribers, the widest network coverage and seemingly the best spectrum assets to deliver its service.

The ASX blue-chip share has leveraged its market position in Australia with regular price increases. Unlocking more revenue from the same number of subscribers should improve its margins, since costs aren’t increasing at the same pace.

Australia is becoming increasingly digital for households, businesses and government, which gives the company defensive earnings. Plus, Australia’s growing population gives the business a tailwind to win more subscribers.

According to Commsec’s projection, the business is forecast to pay an annual dividend per share of 21 cents in FY26. That translates into a possible grossed-up dividend yield of 5.8%, including franking credits.

The business has a strong chance of increasing its dividend in FY27 and is expected to raise its annual payout to 21.5 cents per share, according to projections on Commsec.

The post 2 ASX blue-chip shares offering big dividend yields appeared first on The Motley Fool Australia.

More reading

• How to build passive income for life from the ASX share market
• Why Telstra shares could be a top ASX buy for the new financial year
• ASX 200 retail shares outperform on growing hopes interest rates have peaked
• 3 ASX shares I’d buy and hold for my kids
• Where should I invest inside SMSFs instead of property?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Xero Ltd (ASX: XRO) share price has been one of the worst performers in the S&P/ASX 200 Index (ASX: XJO) in recent history. In the last year alone (at the time of writing), the Xero share price has dropped more than 60%, as the below chart shows.

As an accounting software business, Xero has been one of the victims of the big decline in investor confidence surrounding software companies.

But, I think the business has been significantly oversold, and now looks very good value for three reasons.

Ongoing revenue growth

Firstly, the decline in the share price suggests a bleak future. However, while we can’t know for certain what the future holds (positively or negatively), revenue (and subscriber) numbers remain solid because of a few different elements.

The company recently reported its FY26 results for the 12 months to 31 March 2026. Its customer numbers grew 11% to 4.92 million. Growth is accelerating – its net customer additions (excluding removed long idle subscriptions) improved by 22% to 506,000. That’s a lot of extra revenue flowing through the business!

Its average revenue per user (ARPU) continues to grow thanks to regular price hikes, which isn’t materially hurting the loyalty of subscribers. ARPU rose 23% to $55.44 during the FY26 period.

Those subscribers likely see the huge time-saving and efficiency tools Xero provides as a great benefit. Time-poor business owners (and accountants and bookkeepers) want to complete tasks as quickly as possible.

Thanks to those revenue growth benefits, its annualised monthly recurring revenue (AMRR) jumped 37% to $3.27 billion, and the total lifetime value (LTV) of customers increased 17% to $21 billion.

US expansion

Xero has built a significant market position in New Zealand, Australia and the UK. It also has a growing presence in countries like Singapore, South Africa and Canada.

However, it has struggled to gain much of a foothold in the US, which is a huge market if Xero can get it right. It’s difficult to break into a market that already has such embedded incumbents.

The acquisition of small and medium business payments company Melio may have been costly, but it could unlock the growth and access to more subscribers that Xero has hoped for.

In FY26, it reported US revenue growth of 240% (30% on an organic basis, excluding Melio). If it can continue to grow US revenue in the double digits, I think it has a very good future.

Long-term profit potential

Profitability took a hit in FY26 due to Melio-related acquisition costs, but I think the long-term outlook looks very promising for continued profit growth in the coming years.

As a software business, the company has a lot of operating leverage – its revenue can increase at a much faster pace than its expenses, in a normal financial year.

As revenue continues to grow, I expect earnings to grow quickly. Despite profit headwinds in FY26, free cash flow increased 9% to $554 million. The company can use the rapidly rising cash flow to pay dividends and/or make more bolt-on acquisitions.

For me, long-term profit growth is the key reason I’m interested in the Xero share price.

I think Xero is a very exciting ASX share to own, though it’s not the only stock I’d buy today.

The post 3 reasons why the Xero share price is a buy in July appeared first on The Motley Fool Australia.

More reading

• The Nasdaq just had its worst week in months. Here’s what that means for ASX tech stocks
• Buy, hold, sell: Woodside, Xero, BHP shares
• How to invest $500, $5,000, and $50,000 on the ASX
• Why I’d buy Xero and Block shares with $2,000
• Is the tech recovery finally here for Xero and Wisetech shares?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.